



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## NMS-859

Cat. No.:	HY-15714
CAS No.:	1449236-96-7
Molecular Formula:	C <sub>15</sub> H <sub>12</sub> ClN <sub>3</sub> O <sub>3</sub> S
Molecular Weight:	349.79
Target:	p97
Pathway:	Cell Cycle/DNA Damage
Storage:	<div> Powder -20°C 3 years </div> <div> 4°C 2 years </div> <div> In solvent -80°C 2 years </div> <div> -20°C 1 year </div>



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (142.94 mM; Need ultrasonic)					
	Preparing Stock Solutions	<div>Solvent Concentration</div>	Mass	1 mg	5 mg	10 mg
		1 mM	2.8589 mL	14.2943 mL	28.5886 mL	
		5 mM	0.5718 mL	2.8589 mL	5.7177 mL	
	10 mM	0.2859 mL	1.4294 mL	2.8589 mL		
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline					
	Solubility: ≥ 2.5 mg/mL (7.15 mM); Clear solution					

### BIOLOGICAL ACTIVITY

Description	NMS-859 is a potent, covalent VCP (p97) inhibitor, with IC <sub>50</sub> s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively.
IC <sub>50</sub> & Target	IC <sub>50</sub> : 360 nM (Cellular p97, 1 mM ATP), 370 nM (Cellular p97, 60 μM ATP) <sup>[1]</sup>
In Vitro	<p>NMS-859 is a potent VCP inhibitor, with IC<sub>50</sub>s of 0.37 and 0.36 μM for wild-type VCP in the presence of 60 μM and 1 mM ATP in cells, respectively. NMS-859 shows very weak inhibitory activity against VCP<sup>C522T</sup>. NMS-859 also suppresses the proliferation of cells, with IC<sub>50</sub>s of 3.5 μM and 3.0 μM in HCT116 and HeLa cell lines, respectively<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>

---

## PROTOCOL

### Cell Assay<sup>[1]</sup>

Cells are seeded at 1,600 cells per well in 384-well white clear-bottom plates. Twenty-four hours after seeding, cells are treated with NMS-859 (eight dilution points, in duplicate) and incubated for an additional 72 h at 37°C under a 5% CO<sub>2</sub> atmosphere. Cells are then lysed, and the ATP content in each well is determined using a thermostable firefly luciferase-based assay as a measure of cell viability. IC<sub>50</sub> values are calculated using the percentage of growth of treated cells versus the untreated control<sup>[1]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

[1]. Magnaghi P, et al. Covalent and allosteric inhibitors of the ATPase VCP/p97 induce cancer cell death. Nat Chem Biol. 2013 Sep;9(9):548-56.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA